LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    EuropaBio sat down with new member SenseUp, to find out about the natural evolution approach for novel protein and RNA products

    13/12/2022
    INTERVIEW

    About Georg Schaumann
    Georg studied biology in Düsseldorf and Aachen, before inventing single-cell biosensors for microbial strain development by natural evolution for his PhD at Forschungszentrum Jülich. He started SenseUP as a spin-off project in 2015, and raised funding with Helmholtz-Enterprise, GO-Bio phase I & II accompanied by two seed-financing rounds. SenseUP GmbH began commercial activity in mid 2017 and today has an active team of 12 and has received awards from German, European and global institutions. Georg is a father of two and lives in Cologne.

    Interview with Dr. Georg Schaumann, CEO and Founder at SenseUP

    1) What inspired the foundation of SenseUp?

    SenseUP was founded by scientists with the desire to translate great scientific achievements into real-world applications. We believe that science and technology will strongly contribute to solving the world’s biggest problems. But to do so, they must be  implemented in industrial applications and that’s what SenseUP was founded for and is delivering on now.

    2) What are the policy areas which offer opportunities and potential challenges for SenseUp?

    Opportunities: Bio-technologies such as ours will enable the transition of many industrial sectors away from an oil, chemical or animal base to new solutions that better support environmental goals and a growing population. Policies that support environmental and climate regulation can accelerate this transition.

    Challenges: In Europe, the regulatory process for novelty products is extremely long and complex. We need this to change to avoid innovation migrating to more accommodating parts of the world.

    3) What are your plans for growth?

    Since 2019, SenseUP has been working on an RNA program to explore and identify novel applications with strong commercial value. We have now started developing a range of RNA products based on microbial fermentation using SenseUp’s patented Corynebacterium and natural evolution technology.

    Our aim is to develop sustainable and effective commercial products that are ready for industrial-scale production at low cost and can be launched in the years to come in cooperation with strategic industrial partners.

    4) How do you see SenseUp being able to transform the biotech industry?

    By delivering on our vision! This is: “Enabling a healthy and sustainable future by unlocking the path to valuable proteins and RNA”

    RNA has revolutionary potential as a therapeutic agent for both human and animal health, as well as for use as a biopesticide in agriculture.

    We are targeting animal parasites and plant pathogens that cause financial losses worth billions of Euros, in addition to positive impact on human, animal and environmental health.

    Interview with SenseUp


    Download
    2022_12_G_O_Interview-with-New-Member-SenseUpDownload
    Share
    Communications Team
    Communications Team

    Related posts

    06/02/2026

    OECD: A comparison of the innovation and regulatory environments for biotechnology and biosolutions across the European Union and the United States


    Read more
    03/02/2026

    Ecolab Life Sciences joins EuropaBio: Helping Shape the Future of Life Sciences Manufacturing in Europe


    Read more
    29/01/2026

    EuropaBio Consultation Response: Public Procurement Directives


    Read more

    Important links

    • OECD: A comparison of the innovation and regulatory environments for biotechnology and biosolutions across the European Union and the United States
    • Ecolab Life Sciences joins EuropaBio: Helping Shape the Future of Life Sciences Manufacturing in Europe

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.